Applied Biosystems Introduces Advanced Gene Expression Service Provider Program.FOSTER CITY, Calif. & VANCOUVER, British Columbia British Columbia, province (2001 pop. 3,907,738), 366,255 sq mi (948,600 sq km), including 6,976 sq mi (18,068 sq km) of water surface, W Canada. Geography -- Program Provides Special Bundled Product Offering, Technical and Promotional Support to Service Providers Using Expression Array System Applied Biosystems Applied Biosystems, Inc. (formerly NASDAQ: ABIO) is the original name of a pioneer biotechnology company founded in 1981 in Foster City, California, among the Silicon Valley cities of the southern San Francisco Bay Area. (NYSE NYSE See: New York Stock Exchange :ABI Abi (ā`bī) [short for Abijah], in the Bible, King Hezekiah's mother. (Application Binary Interface) A specification for a specific hardware platform combined with the operating system. ), an Applera Corporation business, today announced the introduction of the Applied Biosystems Advanced Gene Expression Service Provider Program, a new program for service providers who are interested in accessing Applied Biosystems' comprehensive solution for gene expression analysis, including the highly sensitive Adj. 1. highly sensitive - readily affected by various agents; "a highly sensitive explosive is easily exploded by a shock"; "a sensitive colloid is readily coagulated" Expression Array System for whole genome analysis and gold-standard TaqMan(R) Gene Expression Assays for target validation. The program includes a bundled product option for the entire gene expression workflow application A workflow application is where various applications, components and people must be involved in the processing of data to complete an instance of a process. For example, consider a purchase order that moves through various departments for authorization and eventual purchase. and technical and promotional support that is expected to enhance service providers' business offerings. The program, intended to assist service providers in genetic analysis using interpretation tools and content to advance scientific research while helping them achieve necessary return on investment, was announced today in advance of this weekend's annual World Microarray Congress in Vancouver, Canada. The Applied Biosystems Expression Array System forms the technical platform for the program and can be optionally bundled with companion products that comprise Applied Biosystems' whole solution for gene expression analysis, including microarrays for human, mouse, and rat, TaqMan(R) Gene Expression Assays, and Real-Time PCR PCR polymerase chain reaction. PCR abbr. polymerase chain reaction Polymerase chain reaction (PCR) Systems. Additional data analysis and promotional support is included with the Applied Biosystems Advanced Gene Expression Service Provider Program. Participants will have access to the Celera Discovery System(TM) Online Platform and Panther(TM) Protein Classification System, a Service Provider web link on the Applied Biosystems Web site, and on-site seminars to educate customers to help provide increased business opportunities. "Under the program, organizations offering gene expression analysis services can now offer their clients a complete gene expression analysis system backed with a technical and promotional support package from the leader in gene expression technologies," said Catherine M. Burzik, President of Applied Biosystems. The Applied Biosystems Expression Array System is a highly sensitive gene expression detection system. The system detects more genes and achieves more than a 10-fold increase in sensitivity while using less sample for the detection of genes expressed at very low levels compared with conventional fluorescent microarrays. The system uses a chemiluminescence-detection instrument, software, and chemistries to deliver unambiguous gene results that are highly sensitive and reproducible. The PCR process and the 5' nuclease nuclease /nu·cle·ase/ (noo´kle-as) any of a group of enzymes that split nucleic acids into nucleotides and other products. nu·cle·ase n. detection process are covered by patents owned by Roche Molecular System, Inc. and F. Hoffmann-La Roche Ltd ("Roche"). Performing services using these patented processes may require additional licenses from Applied Biosystems or Roche. For more information, visit http://docs.appliedbiosystems.com/pebiodocs/00114098.pdf. About Applera Corporation and Applied Biosystems Applera Corporation consists of two operating groups. The Applied Biosystems Group serves the life science industry and research community by developing and marketing instrument-based systems, consumables, software, and services. Customers use these tools to analyze nucleic acids Nucleic acids The cellular molecules DNA and RNA that act as coded instructions for the production of proteins and are copied for transmission of inherited traits. (DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. and RNA RNA: see nucleic acid. RNA in full ribonucleic acid One of the two main types of nucleic acid (the other being DNA), which functions in cellular protein synthesis in all living cells and replaces DNA as the carrier of genetic ), small molecules, and proteins to make scientific discoveries, develop new pharmaceuticals, and conduct standardized testing. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.7 billion during fiscal 2004. The Celera Genomics Group (NYSE:CRA See Community Reinvestment Act. ) is engaged principally in the discovery and development of targeted therapeutics for cancer, autoimmune and inflammatory diseases. Celera Genomics is leveraging its proteomic, bioinformatic, and genomic capabilities to identify and validate drug targets, and to discover and develop small molecule therapeutics. It is also seeking to advance therapeutic antibody and selected small molecule drug programs in collaboration with global technology and market leaders. Celera Diagnostics, a 50/50 joint venture between Applied Biosystems and Celera Genomics, is focused on discovery, development, and commercialization of diagnostic products. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.applera.com, or by telephoning 800.762.6923. Information about Applied Biosystems is available at http://www.appliedbiosystems.com/. Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "believe," "expect," "plans," and "should" among others. These forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. are based on Applera Corporation's current expectations. The Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 provides a "safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " for such forward-looking statements. In order to comply with the terms of the safe harbor, Applera Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These factors include but are not limited to (1) rapidly changing technology and dependence on the development of new products; (2) Applied Biosystems' dependence on the operation of computer hardware, software, and Internet applications and related technology; (3) unproven use of genomics information to develop or commercialize products; (4) market adoption of the technology; (5) claims for patent infringement patent infringement n. the manufacture and/or use of an invention or improvement for which someone else owns a patent issued by the government, without obtaining permission of the owner of the patent by contract, license or waiver. ; and (6) other factors that might be described from time to time in Applera Corporation's filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Applera does not undertake any duty to update this information, including any forward-looking statements, unless required by law. For Research Use Only. Not for use in diagnostic procedures. Copyright(C) 2005. Applera Corporation. All rights reserved. Applied Biosystems and Celera are registered trademarks and Applera, Celera Diagnostics, Celera Genomics, Celera Discovery System, and Panther are trademarks of Applera Corporation or its subsidiaries in the U.S. and/or certain other countries. TaqMan is a registered trademark of Roche Molecular Systems, Inc. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion